PDS Biotechnology (FRA:EU6) Institutional Ownership: 6.36% (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EU6 PDS Biotechnology Corp FRA:EU6
31 GF Score
Price €0.60
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Institutional Ownership?

PDS Biotechnology FRA:EU6 -0.67% 31 Institutional Ownership is 6.36% as of Jul. 29, 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PDS Biotechnology's institutional ownership is 6.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PDS Biotechnology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PDS Biotechnology's Float Percentage Of Total Shares Outstanding is 96.55%.

PDS Biotechnology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Institutional Ownership Chart

PDS Biotechnology Historical Data

The historical data trend for PDS Biotechnology can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 6.97 6.94 6.05 5.69 5.72 5.71 6.21 6.29 6.09 6.36
FRA:EU6
31GF Score
PDS Biotechnology Corp FRA:EU6
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 6.36% mean?
PDS Biotechnology (FRA:EU6) has a Institutional Ownership of 6.36% as of Jul. 29, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on PDS Biotechnology and its competitors.
Is PDS Biotechnology's Institutional Ownership too high?
PDS Biotechnology's current Institutional Ownership is 6.36%. Overall, PDS Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's Institutional Ownership compare to GRCE and HYPD?
PDS Biotechnology's Institutional Ownership of 6.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current Institutional Ownership is 6.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current Institutional Ownership of 6.36%. The current Institutional Ownership is 6.36%. PDS Biotechnology's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current Institutional Ownership is 6.36% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score

Get the complete analysis for FRA:EU6

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price